亚虹医药1月22日获融资买入2860.35万元，融资余额2.38亿元

Core Viewpoint - Yahui Pharmaceutical has shown significant trading activity with a notable increase in stock price and fluctuations in financing and margin trading, indicating investor interest and potential volatility in the stock. Group 1: Stock Performance - On January 22, Yahui Pharmaceutical's stock rose by 2.01%, with a trading volume of 316 million yuan [1] - The financing buy-in amount on the same day was 28.60 million yuan, while the financing repayment was 37.93 million yuan, resulting in a net financing buy of -9.33 million yuan [1] - As of January 22, the total financing and margin trading balance for Yahui Pharmaceutical was 238 million yuan, accounting for 3.98% of its market capitalization [1] Group 2: Financing and Margin Trading - The financing balance of Yahui Pharmaceutical is at a high level, exceeding the 80th percentile of the past year [1] - On January 22, the company had a margin repayment of 1,956 shares with no shares sold, resulting in a margin balance of 374,000 yuan, which is above the 90th percentile of the past year [1] Group 3: Company Overview - Yahui Pharmaceutical, established on March 16, 2010, is located in the Pudong New Area of Shanghai and was listed on January 7, 2022 [1] - The company's main business involves the research, production, and sales of innovative drugs, with 96.34% of its revenue coming from anti-tumor products [1] Group 4: Financial Performance - As of September 30, 2025, Yahui Pharmaceutical reported a revenue of 216 million yuan, representing a year-on-year growth of 55.74% [2] - The net profit attributable to the parent company was -249 million yuan, showing an increase of 8.08% year-on-year [2] - The number of shareholders decreased to 25,200, while the average circulating shares per person increased by 16.41% to 17,294 shares [2] Group 5: Institutional Holdings - As of September 30, 2025, the seventh largest circulating shareholder of Yahui Pharmaceutical is Penghua Medical Technology Stock A, holding 6.14 million shares, which is a decrease of 401,700 shares from the previous period [2]